A study to evaluate the efficacy and toxicity profile of anti-PD1 MoAbs (Nivolumab, Pembrolizumab) in refractory lymphomas in a real life population
Latest Information Update: 20 Jul 2020
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association